Inovio Pharmaceuticals, Inc. (INO) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 9 Buy, 6 Hold, 2 Sell.
The consensus price target is $6.00, representing an upside of 440.5% from the current price $1.11.
Analysts estimate Earnings Per Share (EPS) of $-4.21 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.95 vs est $-4.21 (beat +6.1%). 2025: actual $-1.81 vs est $-2.27 (beat +20.3%). Analyst accuracy: 84%.
INO Stock — 12-Month Price Forecast
$6.00
▲ +440.54% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Inovio Pharmaceuticals, Inc., the price target is $6.00.
The average price target represents a +440.54% change from the last price of $1.11.
INO Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Inovio Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — INO
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.95
vs Est –$4.21
▲ 6.5% off
2025
Actual –$1.81
vs Est –$2.27
▲ 25.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — INO
65%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 38.7% off
2025
Actual $0.000B
vs Est $0.000B
▼ 31.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
